Advertisement

Topics

Janssen to Develop Bispecific Antibodies based on Zymeworks Platforms in Up-to-$1.4B Deal

04:49 EST 13 Nov 2017 | Genetic Engineering News

Johnson & Johnson’s Janssen Biotech will use Zymeworks’ Azymetric™ and Effector Function Enhancement and Control Technology (EFECT™) platforms to research, develop, and commercialize up to six bispecific antibodies directed to unspecified Janssen therapeutic targets, through a licensing agreement that Zymeworks said today could generate for it up to $1.4 billion-plus. The collaboration is Zymeworks’ sixth with a biopharma giant, and the first since its wholly-owned lead product candidate ZW25, developed through Azymetric, entered clinical trials. “The proceeds from this collaboration will be primarily used to fund the clinical advancement of ZW25, as well as the advancement of our preclinical programs into the clinic,” Zymeworks President and CEO Ali Tehrani, Ph.D., said in a statement. ZW25 is a bispecific antibody designed to treat HER2-expressing cancers by simultaneously binding two non-overlapping epitopes—called biparatopic binding—of HER2, resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein ...

Original Article: Janssen to Develop Bispecific Antibodies based on Zymeworks Platforms in Up-to-$1.4B Deal

NEXT ARTICLE

More From BioPortfolio on "Janssen to Develop Bispecific Antibodies based on Zymeworks Platforms in Up-to-$1.4B Deal"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...